These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 1333276)

  • 1. Subclassification of class I antiarrhythmic drugs: enhanced relevance after CAST.
    Campbell TJ
    Cardiovasc Drugs Ther; 1992 Oct; 6(5):519-28. PubMed ID: 1333276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Class-I antiarrhythmic drugs].
    Kuga K; Sugishita Y
    Nihon Rinsho; 1996 Aug; 54(8):2110-6. PubMed ID: 8810785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [New aspects of the electrophysiologic effect of antiarrhythmic agents].
    Antoni H; Weirich J
    Herz; 1990 Apr; 15(2):61-9. PubMed ID: 2188893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proarrhythmic response to sodium channel blockade. Theoretical model and numerical experiments.
    Starmer CF; Lastra AA; Nesterenko VV; Grant AO
    Circulation; 1991 Sep; 84(3):1364-77. PubMed ID: 1653123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Why are some antiarrhythmic drugs proarrhythmic? Cardiac arrhythmia study by bifurcation analysis.
    Chay TR
    J Electrocardiol; 1995; 28 Suppl():191-7. PubMed ID: 8656110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New class III antiarrhythmic drugs.
    Katritsis D; Camm AJ
    Eur Heart J; 1993 Nov; 14 Suppl H():93-9. PubMed ID: 8293759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Classification of antiarrhythmic agents: electropharmacologic basis and clinical relevance.
    Coromilas J
    Cardiovasc Clin; 1992; 22(1):97-116. PubMed ID: 1309443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ionic mechanisms for prolongation of refractoriness and their proarrhythmic and antiarrhythmic correlates.
    Roden DM
    Am J Cardiol; 1996 Aug; 78(4A):12-6. PubMed ID: 8780324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. On the mechanism of action of antiarrhythmic agents.
    Grant AO
    Am Heart J; 1992 Apr; 123(4 Pt 2):1130-6. PubMed ID: 1313200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ischemic modulation of vulnerable period and the effects of pharmacological treatment of ischemia-induced arrhythmias: a simulation study.
    Cimponeriu A; Starmer CF; Bezerianos A
    IEEE Trans Biomed Eng; 2003 Feb; 50(2):168-77. PubMed ID: 12665030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A rational scientific basis for subclassification of antiarrhythmic drugs.
    Harrison DC
    Trans Am Clin Climatol Assoc; 1986; 97():43-52. PubMed ID: 3837966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reverse use dependence of antiarrhythmic class Ia, Ib, and Ic: effects of drugs on the action potential duration?
    Langenfeld H; Köhler C; Weirich J; Kirstein M; Kochsiek K
    Pacing Clin Electrophysiol; 1992 Nov; 15(11 Pt 2):2097-102. PubMed ID: 1279606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ischemia enhances use-dependent sodium channel blockade by pilsicainide, a class IC antiarrhythmic agent.
    Sadanaga T; Ogawa S
    J Am Coll Cardiol; 1994 May; 23(6):1378-81. PubMed ID: 8176096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overview of the clinical pharmacology of antiarrhythmic drugs.
    Woosley RL; Funck-Brentano C
    Am J Cardiol; 1988 Jan; 61(2):61A-69A. PubMed ID: 2447771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of antiarrhythmic drugs on canine ventricular arrhythmia models: which electrophysiological characteristics of drugs are related to their effectiveness?
    Hashimoto K; Haruno A; Matsuzaki T; Sugiyama A; Akiyama K
    Cardiovasc Drugs Ther; 1991 Aug; 5 Suppl 4():805-17. PubMed ID: 1657110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential analysis of frequency-dependent effects of antiarrhythmic drugs: importance of the saturation behavior of frequency-dependent sodium-channel blockade.
    Weirich J; Hohnloser S; Antoni H
    J Cardiovasc Pharmacol; 1992; 20 Suppl 2():S8-16. PubMed ID: 1279314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential analysis of the frequency-dependent effects of class 1 antiarrhythmic drugs according to periodical ligand binding: implications for antiarrhythmic and proarrhythmic efficacy.
    Weirich J; Antoni H
    J Cardiovasc Pharmacol; 1990 Jun; 15(6):998-1009. PubMed ID: 1694924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cardiac vulnerable period and reentrant arrhythmias: targets of anti- and proarrhythmic processes.
    Starmer CF
    Pacing Clin Electrophysiol; 1997 Feb; 20(2 Pt 2):445-54. PubMed ID: 9058848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiarrhythmic drug therapy: new drugs and changing concepts.
    Reiser HJ; Sullivan ME
    Fed Proc; 1986 Jul; 45(8):2206-12. PubMed ID: 2873062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New evolvement of antiarrhythmic drugs].
    Kanno M
    Nihon Yakurigaku Zasshi; 1993 Sep; 102(3):215-23. PubMed ID: 8406233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.